PMID- 30562433
OWN - NLM
STAT- MEDLINE
DCOM- 20190503
LR  - 20190503
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 74
IP  - 8
DP  - 2016 Aug
TI  - [Medical treatments of reflux esophagitis - Proton pump inhibitors and histamine 
      H2 receptor antagonists -].
PG  - 1304-1310
AB  - Inhibitors of gastric acid secretion have been used as main drugs for the 
      treatment of reflux esophagitis. Histamine H2 receptor antagonists (H2RA) and 
      proton pump inhibitors(PPI) are the key drugs in acid inhibitors. Acid inhibition 
      after the administration of H2RA quickly appears and its effect is potent during 
      the nocturnal period. However, their acid inhibitory effect becomes attenuated 
      because of the tolerance phenomenon only after 2-week-long oral administration. 
      On the other hand, potent acid inhibition by PPI continues for long period and it 
      is more potent during the day-time period when gastro-esophageal refluxes 
      frequently occur. From the different characteristics of the two drugs, PPI is 
      used as the first line thera- peutic drug for the treatment of reflux 
      esophagitis, while H2RA is used as a su plementary drug for the patients with 
      nocturnal refluxes.
FAU - Kinoshita, Yoshikazu
AU  - Kinoshita Y
FAU - Ishimura, Norihisa
AU  - Ishimura N
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - *Esophagitis, Peptic/drug therapy
MH  - *Gastroesophageal Reflux/drug therapy
MH  - *Histamine H2 Antagonists/therapeutic use
MH  - Humans
MH  - *Proton Pump Inhibitors/therapeutic use
EDAT- 2016/08/01 00:00
MHDA- 2016/08/01 00:01
CRDT- 2018/12/19 06:00
PHST- 2018/12/19 06:00 [entrez]
PHST- 2016/08/01 00:00 [pubmed]
PHST- 2016/08/01 00:01 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2016 Aug;74(8):1304-1310.